Issued: Philadelphia, PA
\nFor media and investors only
","shortDescription":"Submission supported by positive phase III data in patients with uncomplicated urogenital gonorrhoea in EAGLE 1 trial.","image":null,"downloadLink":{"text":"Download (PDF - 212.3KB)","href":"/media/0qea12sa/gepo-gc-us-filing-acceptance_sea_final.pdf","title":"Opens in a new window","target":"_blank"},"tags":[]},"components":[{"type":"rich-text","text":"GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral option for the treatment of uncomplicated urogenital gonorrhea in patients 12 years of age and older (weighing ≥45 kg). The US FDA has assigned a Prescription Drug User Fee Act action date of December 11, 2025. In March 2025, gepotidacin was approved by the US FDA under the licensing name Blujepa (1,500mg administered orally twice daily for five days) as oral treatment for female adult and pediatric patients 12 years of age and older (weighing ≥40 kg) with uncomplicated urinary tract infection (uUTI).3
\nGonorrhea is a common, sexually transmitted infection caused by Neisseria gonorrhoeae, which has been recognized by the World Health Organization as a priority pathogen2 and an urgent public health threat by the US Centers for Disease Control and Prevention (CDC).4 It affects both men and women and if left untreated or inadequately treated, it can lead to infertility and other sexual and reproductive health complications. There were more than 600,000 cases of gonorrhea reported in the United States in 2023 according to the CDC, making it the second most commonly reported sexually transmitted infection in the country.5 There is currently no vaccine licensed in the US for the prevention of gonorrhea infection and the standard of care is injectable treatment which may not be suitable or available for all patients.6
\nThe US application is based on results from the EAGLE-1 phase III trial recently published in The Lancet, showing that gepotidacin (oral, two doses of 3,000mg) was non-inferior, with 92.6% (187/202, [95% CI 88·0 to 95·8]) success rates at urogenital site when compared to 91.2% (186/204, [95% CI 86.4-94.7]) success rates for intramuscular ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy, a leading combination treatment regimen for gonorrhea. Additionally, there were no failures at the urogenital site due to bacterial persistence of N. gonorrhoeae in either treatment arm. The safety and tolerability profile of gepotidacin in the EAGLE-1 trial was consistent with results seen in previous clinical trials, with no serious drug related adverse events observed in either the gepotidacin or the comparator arm. The most common reported adverse reactions were mild (45% Grade 1) to moderate (29% Grade 2) gastrointestinal events.1
\nThis is the second major indication filed in the US for gepotidacin, and review of regulatory submissions for the uUTI indication is also ongoing in the UK and Australia.
\nThe development of gepotidacin has been funded in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Agreement number HHSO100201300011C and with federal funds awarded by the US Department of Defense’s Threat Reduction Agency under agreement number HDTRA1-07-9-0002.
\nGepotidacin, discovered by GSK scientists, is a bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct binding site, a novel mechanism of action, and for most pathogens, provides well-balanced inhibition of two different Type II topoisomerase enzymes. This provides activity against Neisseria gonorrhoeae and most target uropathogens (such as Escherichia coli and Staphylococcus saprophyticus), including isolates resistant to current antibiotics. Due to this well-balanced inhibition for most pathogens, a single target-specific mutation may not significantly impact gepotidacin activity.
\nPlease see full Prescribing Information including Medication Guide, available here.
\nThe EAGLE-1 trial (NCT04010539) is part of a comprehensive global phase III clinical program for gepotidacin in adults and adolescents including:
\nEAGLE-1 (non-inferiority urogenital gonorrhea trial) compared the efficacy and safety of gepotidacin (oral, two doses of 3,000mg) to intramuscular ceftriaxone (500mg) plus oral azithromycin (1,000mg) in approximately 600 patients with uncomplicated urogenital gonorrhea. The data were presented at ESCMID in April 2024 and published in The Lancet in April 2025.1
\nEAGLE-2 and EAGLE-3 (non-inferiority uUTI trials) compared the efficacy and safety of gepotidacin (1,500mg administered orally twice daily for five days) to nitrofurantoin (100mg administered orally twice daily for five days). The data were first presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in 2023.8
\nGSK has pioneered innovation in infectious diseases for over 70 years, and the Company’s pipeline of medicines and vaccines is one of the largest and most diverse in the industry, with a goal of developing preventive and therapeutic treatments for multiple disease areas or diseases with high unmet needs globally. Our expertise and capabilities in infectious disease strongly position us to help prevent disease and mitigate the challenge of antimicrobial resistance (AMR).
\nBLUJEPA is indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.
\nTo reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.
\nBLUJEPA is contraindicated in patients with a history of severe hypersensitivity to BLUJEPA
\nA dose and concentration-dependent prolongation of the QTc interval has been observed with BLUJEPA. Avoid use of BLUJEPA in patients with a history of QTc prolongation or with relevant pre-existing cardiac disease, patients taking antiarrhythmic agents, and in patients receiving drugs that prolong the QT interval. Due to an increase in BLUJEPA exposure, avoid concomitant administration of BLUJEPA with strong CYP3A4 inhibitors, in patients with severe hepatic impairment (Child-Pugh Class C), and in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min)
\nDysarthria and other adverse reactions potentially attributed to acetylcholinesterase inhibition have been reported with BLUJEPA, an acetylcholinesterase inhibitor. Increased cholinergic effects can be associated with severe adverse effects including atrioventricular block, bradycardia, bronchospasm, seizures/convulsions, and vasovagal syncope. Monitor patients with underlying medical conditions that may be exacerbated by acetylcholinesterase inhibition and patients receiving succinylcholine-type neuromuscular blocking agents, systemic anticholinergic medications, or non-depolarizing neuromuscular blocking agents
\nHypersensitivity reactions, including anaphylaxis, have been reported in patients receiving BLUJEPA. If an allergic reaction to BLUJEPA occurs, discontinue the drug and institute appropriate supportive measures.
\nClostridioides difficile Infection (CDI) has been reported with nearly all systemic antibacterial agents, including BLUJEPA. Evaluate patients who develop diarrhea
\nThe most common adverse reactions occurring in ≥1% of patients are diarrhea, nausea, abdominal pain, flatulence, headache, soft feces, dizziness, vomiting, and vulvovaginal candidiasis
\nCYP3A4 Inhibitors: Avoid coadministration of BLUJEPA with strong CYP3A4 inhibitors due to increased gepotidacin exposure
\nCYP3A4 Inducers: Avoid coadministration of BLUJEPA with strong CYP3A4 inducers due to decreased gepotidacin exposure
\nCYP3A4 Substrates: Avoid coadministration of BLUJEPA with drugs that are extensively metabolized by CYP3A4 and have a narrow therapeutic window
\nDigoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA
\nRenal Impairment: Avoid use of BLUJEPA in patients with severe renal impairment with eGFR <30 ml/min, including those receiving dialysis
\nHepatic Impairment: Avoid use of BLUJEPA in patients with severe hepatic impairment (Child-Pugh Class C)
\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
\nGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q2 Results for 2025.
","useGreyBackground":false,"fullWidth":false},{"type":"references","title":"References","references":[{"anchorName":"","text":"Ross J et al, “Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study” in The Lancet, 2025; 405: 1608–20; https://doi.org/10.1016/ S0140-6736(25)00628-2
"},{"anchorName":"","text":"WHO. bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Available at: https://www.who.int/publications/i/item/9789240093461 Last accessed: August 2025
"},{"anchorName":"","text":"GSK. Blujepa approved by US FDA for treatment of uncomplicated urinary tract infections. Available at: https://www.gsk.com/en-gb/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/ Last accessed: August 2025
"},{"anchorName":"","text":"CDC. Antibiotic Resistance Threats Report. Available at: https://www.cdc.gov/antimicrobial-resistance/media/pdfs/covid19-impact-report-508.pdf Last accessed: August 2025
"},{"anchorName":"","text":"CDC. National Overview of STIs in 2023. Available at: https://www.cdc.gov/sti-statistics/annual/summary.html. Last accessed: August 2025
"},{"anchorName":"","text":"CDC. STI treatment guideline. Available: https://www.cdc.gov/std/treatment-guidelines/default.htm Last accessed: August 2025
"},{"anchorName":"","text":"GSK. EAGLE 1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments. Available at:https://www.gsk.com/en-gb/media/press-releases/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc/ Last accessed: August 2025.
"},{"anchorName":"","text":"GSK. Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years. Available at: https://www.gsk.com/en-gb/media/press-releases/gepotidacin-s-positive-phase-iii-data-shows-potential-to-be-the-first-in-a-new-class-of-oral-antibiotics-for-uncomplicated-urinary-tract-infections/ Last accessed: August 2025.
"}]},{"type":"varied-signpost-grid","title":"You might also like","layoutPattern":4,"pages":[{"title":"Press releases","content":"Keep up to date with our news and recent announcements","image":{"src":"/media/viygjccz/person-getting-interviewed-2.jpg?rxy=0.46666666666666667,0.69125&width=427&height=533&format=webp&quality=100&v=1dbe122680aaf70&hmac=6971c33051887d8daee1a525499d4ca9ecefe83eb84a387ddef58f4c188ee790","alt":"two people on air.","darkModeSrc":"/media/viygjccz/person-getting-interviewed-2.jpg?rxy=0.46666666666666667,0.69125&width=427&height=533&format=webp&quality=90&v=1dbe122680aaf70&hmac=a8500ca648c00b479618aa82cb62a8ed9b37fac6c042ef068967b72ee32d9975"},"link":{"text":"Press releases","href":"/en-us/media/press-releases/","openInNewWindowText":null}},{"title":"Media","content":"US resources, press releases, information on our social media channels, and our photo and video library","image":{"src":"/media/qnlgziui/two-people-about-to-go-on-air-1.jpg?width=427&height=533&format=webp&quality=100&v=1dc83ee6344a350&hmac=1508c8ba4218f397a0e6c9237fe8389f7528156b54cd3721712ec0c71421953a","alt":"Two people on set.","darkModeSrc":"/media/qnlgziui/two-people-about-to-go-on-air-1.jpg?width=427&height=533&format=webp&quality=90&v=1dc83ee6344a350&hmac=e8d4e5859b2d88cfba8536b272d0e1f3dc6510c953562870945741fdcef6e5bc"},"link":{"text":"Media","href":"/en-us/media/","openInNewWindowText":null}},{"title":"Company","content":"We unite science, technology and talent to get ahead of disease together","image":{"src":"/media/suilv4ve/dna-and-tech-science-image-rgb.jpg?width=427&height=533&format=webp&quality=100&v=1dcd7c357a61910&hmac=edf8eb7548169498126d063682058df2ec8aa5b098e242267864cd0abb999345","alt":"DNA And Tech Science Image","darkModeSrc":"/media/suilv4ve/dna-and-tech-science-image-rgb.jpg?width=427&height=533&format=webp&quality=90&v=1dcd7c357a61910&hmac=614850e59761a78ef5a40ccdee87d3a8f856175d66147674c7880dde66a2cab8"},"link":{"text":"Company","href":"/en-us/company/","openInNewWindowText":null}}],"hidePageDescription":false,"useGreyBackground":false}]},"id":5899,"docCheckLogout":null,"pageType":"pressReleasePage","languageCode":"en-US","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-us/","openInNewWindowText":null},{"text":"Media","href":"/en-us/media/","openInNewWindowText":null},{"text":"Press releases","href":"/en-us/media/press-releases/","openInNewWindowText":null},{"text":"Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhea","href":"/en-us/media/press-releases/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhea/","openInNewWindowText":null}]},"pageName":"Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhea","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-us/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":false,"text":"United States (EN)"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"Dark Mode","tooltipText":"Switch to dark mode to head towards a more sustainable world together. More info
"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"locationSelector":{"text":"Change location","href":"/en-us/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-us/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science US edition","url":"/en-us/behind-the-science-us-edition/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-us/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-us/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"Respiratory, immunology and inflammation","url":"/en-us/company/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-us/company/oncology/","nodes":[{"title":"Myelofibrosis","url":"/en-us/company/oncology/myelofibrosis/","nodes":[],"isActive":false},{"title":"Ovarian cancer","url":"/en-us/company/oncology/ovarian-cancer/","nodes":[],"isActive":false},{"title":"Endometrial cancer","url":"/en-us/company/oncology/endometrial-cancer/","nodes":[],"isActive":false},{"title":"Multiple myeloma","url":"/en-us/company/oncology/multiple-myeloma/","nodes":[],"isActive":false},{"title":"Rectal cancer","url":"/en-us/company/oncology/rectal-cancer/","nodes":[],"isActive":false}],"isActive":false},{"title":"HIV","url":"/en-us/company/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-us/company/infectious-diseases/","nodes":[{"title":"Vaccines","url":"/en-us/company/infectious-diseases/vaccines/","nodes":[],"isActive":false},{"title":"Flu","url":"/en-us/company/infectious-diseases/flu/","nodes":[],"isActive":false},{"title":"Shingles (Herpes Zoster)","url":"/en-us/company/infectious-diseases/shingles-herpes-zoster/","nodes":[],"isActive":false},{"title":"RSV (Respiratory Syncytial Virus)","url":"/en-us/company/infectious-diseases/rsv-respiratory-syncytial-virus/","nodes":[],"isActive":false},{"title":"Meningitis","url":"/en-us/company/infectious-diseases/meningitis/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Global Outstanding people","image":{"src":"/media/kjtduuwb/20250115-extra-6-phl-small.jpg?width=329&height=185&format=webp&quality=100&v=1dbe12238ee2370&hmac=2ef3f6f97d5f1b7f7620eb52fb06639a23e819c47ca25dec024ddd025f705ea1","alt":"Two people walking in an office","darkModeSrc":"/media/kjtduuwb/20250115-extra-6-phl-small.jpg?width=329&height=185&format=webp&quality=90&v=1dbe12238ee2370&hmac=8fed218c6c7076c57c4d14a200a2b057b55f9c61e95d19399176255bc9baf00b"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/outstanding-people/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global policy positions","image":{"src":"/media/diaofnw2/20250115-extra-14-phl.jpg?width=329&height=185&format=webp&quality=100&v=1dbe122233e8880&hmac=2843adf64f40a5bf3de75b028bccdd6f7e7ad0b367dd95d1ef0d77dbbbd245d1","alt":"An employee attending an online meeting","darkModeSrc":"/media/diaofnw2/20250115-extra-14-phl.jpg?width=329&height=185&format=webp&quality=90&v=1dbe122233e8880&hmac=102ff4fd1b2767c7376ad2347999e6f1009bb604978912c5b09cb32e38926b06"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/policy-positions","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-us/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-us/innovation/therapeutic-areas/","nodes":[],"isActive":false},{"title":"Technologies","url":"/en-us/innovation/technologies/","nodes":[],"isActive":false},{"title":"Clinical studies","url":"/en-us/innovation/clinical-studies/","nodes":[{"title":"Representative clinical trials","url":"/en-us/innovation/clinical-studies/representative-clinical-trials/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Global pipeline","image":{"src":"/media/zr0acsx2/20281231-c1-innovation-um.jpg?width=329&height=185&format=webp&quality=100&v=1dc8fa7a9f728d0&hmac=2873b97da279e11f73602f7a9cba5364fde2775011021a467cd91bac8aed2463","alt":"A close-up shot of scientist's hands handling a vial","darkModeSrc":"/media/zr0acsx2/20281231-c1-innovation-um.jpg?width=329&height=185&format=webp&quality=90&v=1dc8fa7a9f728d0&hmac=207c4878e5f6b152b49bdd1d8256831c308ecc21effe806b26dbc91d412a6046"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global Behind the science magazine","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?width=329&height=185&format=webp&quality=100&v=1dcc04016a69c90&hmac=cf5a111e425b275e7ebdbab1c025eeb8ed09857c9edee9517b9bad6703278756","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?width=329&height=185&format=webp&quality=90&v=1dcc04016a69c90&hmac=42086965489af81a1e9dd63c4b4e2f77e67b5b5632db5792095446137d265619"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/behind-the-science-magazine/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-us/products/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-us/responsibility/","nodes":[{"title":"Inclusion","url":"/en-us/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"US charitable investments","url":"/en-us/responsibility/us-charitable-investments/","nodes":[{"title":"Charitable grants","url":"/en-us/responsibility/us-charitable-investments/charitable-grants/","nodes":[],"isActive":false}],"isActive":false},{"title":"Ethical standards","url":"/en-us/responsibility/ethical-standards/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Access to medicines","image":{"src":"/media/q2cllvad/20271231-a1-careers-up.jpg?width=329&height=185&format=webp&quality=100&v=1dbe1221dd270f0&hmac=61c9705da6f36ac0e7cba8f547f7b5d85363406b25ff4bacd61aff9f50212908","alt":"A scientist checking experiment results in the lab","darkModeSrc":"/media/q2cllvad/20271231-a1-careers-up.jpg?width=329&height=185&format=webp&quality=90&v=1dbe1221dd270f0&hmac=ea90cef777b2a56b33cd9ac04981b2436c9374eda1cf2ea7fc3abb5a93e87d0c"},"link":{"text":"FEATURED WEBSITE","href":"https://www.gskforyou.com/","openInNewWindowText":null}},{"text":"Global Responsibility ","image":{"src":"/media/e5nbvffs/20250115-f4-ethical-standards-um.jpg?width=329&height=185&format=webp&quality=100&v=1dbe1221ed9f5e0&hmac=3b10e3accd9c56240ff039c54c418d8619989b0dded4c20ce1387060c7d734a5","alt":"A smiling scientist posing in the lab","darkModeSrc":"/media/e5nbvffs/20250115-f4-ethical-standards-um.jpg?width=329&height=185&format=webp&quality=90&v=1dbe1221ed9f5e0&hmac=60df253e2421316d25703ed5888efda432d001dd24362a79bd5cd7a21dfb6f45"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/responsibility/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-us/media/","nodes":[{"title":"Press releases","url":"/en-us/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-us/media/media-contacts/","nodes":[],"isActive":false},{"title":"In Focus","url":"/en-us/media/in-focus/","nodes":[{"title":"Flu is a Family Affair","url":"/en-us/media/in-focus/flu-is-a-family-affair/","nodes":[],"isActive":false}],"isActive":false}],"isActive":true,"promos":[{"text":"Global press releases","image":{"src":"/media/svplhxgn/20271231-h2-visit-our-global-careers-site-link-um.jpg?width=329&height=185&format=webp&quality=100&v=1dbe12238bed610&hmac=8955fd4d2a54376e2bb8cccbd57ac9bac45c25c687fbd94389241becab45fd88","alt":"Two employees discussing work in the office","darkModeSrc":"/media/svplhxgn/20271231-h2-visit-our-global-careers-site-link-um.jpg?width=329&height=185&format=webp&quality=90&v=1dbe12238bed610&hmac=c6a836ccd89903607764c41c1e93f2d0293fdc5d988b6e03b23450d4deea8bba"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/media/press-releases/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-us/careers/","nodes":[{"title":"Search jobs","url":"/en-us/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Life at GSK","url":"/en-us/careers/life-at-gsk/","nodes":[{"title":"Employment rights under federal law","url":"/en-us/careers/life-at-gsk/employment-rights-under-federal-law/","nodes":[],"isActive":false}],"isActive":false},{"title":"Experienced professionals","url":"/en-us/careers/experienced-professionals/","nodes":[{"title":"A career in oncology","url":"/en-us/careers/experienced-professionals/a-career-in-oncology/","nodes":[],"isActive":false},{"title":"A career in Boston","url":"/en-us/careers/experienced-professionals/a-career-in-boston/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-us/careers/early-careers/","nodes":[{"title":"Apprentices","url":"/en-us/careers/early-careers/apprentices/","nodes":[],"isActive":false},{"title":"Internships and co-ops","url":"/en-us/careers/early-careers/internships-and-co-ops/","nodes":[],"isActive":false},{"title":"Scientific leadership program","url":"/en-us/careers/early-careers/scientific-leadership-program/","nodes":[],"isActive":false},{"title":"Commercial development program","url":"/en-us/careers/early-careers/commercial-development-program/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans at GSK","url":"/en-us/careers/veterans-at-gsk/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global how we hire","image":{"src":"/media/3u2dneiw/20271231-a3-contact-us-phl.jpg?width=329&height=185&format=webp&quality=100&v=1dbe12236d41d10&hmac=328fbee1bedb9f64e0987b415050708eee42af60fb57bb28c3525f0ad9887539","alt":"Three employees meeting in the office","darkModeSrc":"/media/3u2dneiw/20271231-a3-contact-us-phl.jpg?width=329&height=185&format=webp&quality=90&v=1dbe12236d41d10&hmac=623a6cede3a6a8305be8d41f686b04ebf0a0b96390547704eb65053a6b84f63f"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/how-we-hire/","openInNewWindowText":null}},{"text":"Global graduate program","image":{"src":"/media/xrsfni0a/20281231-h4a-achieve-your-career-goals-up.jpg?width=329&height=185&format=webp&quality=100&v=1dbe1221e21c970&hmac=cc7acb6f8a166a2c48c403a01d54e007e1997acab9c92c5adf6b49341a656171","alt":"A smiling scientist posing in the lab","darkModeSrc":"/media/xrsfni0a/20281231-h4a-achieve-your-career-goals-up.jpg?width=329&height=185&format=webp&quality=90&v=1dbe1221e21c970&hmac=c6f3880c990298f0d58ebe0f38e2662f7616d2695bfcc1b3c9550db55a4ee053"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","openInNewWindowText":null}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1702","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-us/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This is our US website, intended for US audiences only. Other market sites can be reached by visiting our location selector.
\n© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nRegistered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG
","modernSlaveryStatement":null,"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on LinkedIn","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gskus?igsh=dDl0NjZmbmlia3F1","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.threads.com/@gskus","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Threads","customIcon":null,"showPopupMenu":false,"type":"Threads"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Facebook","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Youtube","customIcon":null,"showPopupMenu":false,"type":"Youtube"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"GSK Global website","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Locations selector","href":"/en-us/locations/","openInNewWindowText":null},{"text":"Global Behind the science","href":"https://www.gsk.com/en-gb/behind-the-science/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSKPro for HCPs","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Business to Business","href":"/en-us/business-to-business-in-the-us/","openInNewWindowText":null},{"text":"Supplier website","href":"https://supplier.gsk.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the science US edition","href":"/en-us/behind-the-science-us-edition/","openInNewWindowText":null},{"text":"Company","href":"/en-us/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-us/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-us/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-us/responsibility/","openInNewWindowText":null},{"text":"Media","href":"/en-us/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-us/careers/","openInNewWindowText":null}]},{"columnTitle":"Global investors","links":[{"text":"Shareholders","href":"https://www.gsk.com/en-gb/investors/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Quarterly results","href":"https://www.gsk.com/en-gb/investors/quarterly-results/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Financial reports","href":"https://www.gsk.com/en-gb/investors/financial-reports/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Share price analysis","href":"https://www.gsk.com/en-gb/investors/dividend-and-share-price/","openInNewWindowText":null},{"text":"Product pipeline","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-us/contact-us/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-us/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-us/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-us/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-us/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-us/privacy-notice/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"About our ads","href":"/en-us/about-our-ads/","openInNewWindowText":null},{"text":"Sitemap","href":"/en-us/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"Submission supported by positive phase III data in patients with uncomplicated urogenital gonorrhoea in EAGLE 1 trial.","og":[{"property":"og:title","content":"Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhea"},{"property":"og:description","content":"Submission supported by positive phase III data in patients with uncomplicated urogenital gonorrhoea in EAGLE 1 trial."},{"property":"og:image","content":"https://us.gsk.com/media/gdvhctix/scientist-testing-biological-samples.jpg?width=600&format=webp&quality=100&v=1dcc1f03f5ccb30&hmac=e396e915444550f15ca2a3572dd6cdae647c190fdaebdf7952a75b1c99f46bb6"},{"property":"og:url","content":"https://us.gsk.com/en-us/media/press-releases/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhea/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhea"},{"name":"twitter:description","content":"Submission supported by positive phase III data in patients with uncomplicated urogenital gonorrhoea in EAGLE 1 trial."},{"name":"twitter:image","content":"https://us.gsk.com/media/gdvhctix/scientist-testing-biological-samples.jpg?width=600&format=webp&quality=100&v=1dcc1f03f5ccb30&hmac=e396e915444550f15ca2a3572dd6cdae647c190fdaebdf7952a75b1c99f46bb6"},{"name":"twitter:url","content":"https://us.gsk.com/en-us/media/press-releases/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhea"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":true,"title":"You are leaving our website","texts":"The information you are about to be referred to may not comply with the local regulatory requirements. Further information relevant to the local environment is available from the company or via the Product Information.
","continueText":"Continue","cancelText":"Cancel","exclusionUrls":["https://www.gsk.com","https://www.facebook.com/GSK","http://doingmoreintheus.gsk.com/en-us/map-regions/","https://www.gsk.com/en-gb","https://www.gsk.com/en-gb/investors/quarterly-results/","https://www.gsk.com/en-gb/about-us/vaccines/why-you-don-t-outgrow-vaccination/","https://www.gsk.com/en-gb/behind-the-science/patients-consumers/eggs-in-manufacturing/","https://innovation.gsk.com/","http://doingmoreintheus.gsk.com/en-us/map-regions/north-carolina/doing-more-on-moore-drive-in-the-research-triangle-park/","http://doingmoreintheus.gsk.com/en-us/map-regions/pennsylvania/gsk-navy-yard-where-we-do-more-with-less/","https://www.gsk.com/en-gb/about-us/save-the-children-partnership","https://www.gskgrants.com","https://www.gskforyou.com/","http://fortherecord.payments.us.gsk.com","https://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","http://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","https://www.gsk.com/en-gb/products/stiefel-dermatology/","https://www.gsk.com/en-gb/products/viiv-healthcare/","https://www.contactus.gsk.com/callback/index.html","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsksource.com/pharma/content/gsk/source/us/en.html","http://www.msds-gsk.com/","https://www.gsk.com/en-gb/investors/shareholder-information/","http://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/investors/corporate-reporting/","https://www.gsk.com/en-gb/investors/product-pipeline/","http://www.gskgrants.com/","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsk.com/media/2941/human-rights-statement-policy.pdf","http://www.gsk.com/media/280848/human-rights-statement-policy.pdf","http://www.gsk.com/en-gb/research/rd-locations/pharmaceuticals/","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","http://twitter.com/GSK","http://www.youtube.com/GSK","http://www.flickr.com/photos/glaxosmithkline","http://www.linkedin.com/company/glaxosmithkline","https://www.instagram.com/gsk/ ","http://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/","https://www.gsk.com/en-gb/behind-the-science/our-people/from-tv-to-tackling-lupus-why-alex-moved-from-media-to-medicine/","http://www.gskforyou.com/","http://us.gsk.com/en-us/behind-the-science/?tag=Corporate+responsibility","https://www.gskforyou.com/prescription-resource-assistance/immunology-respiratory/","https://www.contactus.gsk.com/callback.html","https://www.gsk.com/en-gb/about-us/governance/global-compliance/","https://www.gsk.com/en-gb/careers/physicians/","https://www.gsk.com/en-gb/careers/job-finder/","https://www.gsk.com/en-gb/contact-us/worldwide/","https://access.gsk.com/password/","https://access.gsk.com/selfservice/static/login.jsp?TYPE=33554433&REALMOID=06-c7edf5ec-5585-100d-83b1-84797f88fc89&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-90R5K5a0NsTyKRhPyTIn3A3B5ovKkqcehflGRUrUNusjZdRaPY%2bWUozEFizs1bMg&TARGET=-SM-https%3a%2f%2fuksah%2egsk%2ecom%2fswh_uk_win_ns%2fcommunications%2femployee%2femployees%2ehtm","https://www.gsk.com/en-gb/responsibility/operating-responsibly/working-with-third-parties/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://ascend.cvmsolutions.com/Account/Login?client=gsk","https://twitter.com/GSKUS","https://twitter.com/GSK","https://www.gsk.com/media/5097/our-approach-to-responsible-business_sept-18.pdf","https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/","https://www.gsk.com/media/2538/gsk-materiality-process.pdf","https://www.gsk.com/en-gb/responsibility/access-to-healthcare/","https://www.gsk.com/en-gb/responsibility/our-people/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/","https://www.gsk.com/media/4552/our-code-of-practice.pdf","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=10","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.instagram.com/gsk/","https://twitter.com/gsk","https://twitter.com/gskus","https://www.youtube.com/GSK","https://www.gsk.com/en-gb/media/resource-centre/","https://www.gsk.com/en-gb/media/image-and-video-library/","https://www.gsk.com/en-gb/media/rss-feeds/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2017/","https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/","https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/","https://www.gsk.com/en-gb/careers/experienced-professionals/manufacturing-and-supply/","https://www.gsk.com/en-gb/careers/experienced-professionals/marketing-and-communications/","https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/","https://www.gsk.com/en-gb/careers/experienced-professionals/sales/","https://www.gsk.com/media/5041/rd-update-slides-hal-barron.pdf","https://www.gsk.com/en-gb/careers/meet-our-people/","https://www.gsk.com/en-gb/responsibility/our-people/employee-volunteering/","https://www.gsk.com/en-gb/careers/postgraduate-opportunities/","https://gskearlytalent.avature.net/landingpage","https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/future-leaders-graduate-programme/","https://www.gsk.com/en-gb/responsibility/our-people/volunteer-stories/","https://www.gsk.com/en-gb/partnerships/bioelectronics-research-network/","https://www.gsk.com/en-gb/research/our-approach/open-innovation/","https://www.gsk.com/en-gb/careers/careers-search/?r=USA","https://www.linkedin.com/company/gsk-canada/","https://www.linkedin.com/company/gsk_consumer_healthcare_india/","https://www.linkedin.com/company/gsk-pharmaceuticals-india/","https://www.linkedin.com/company/glaxosmithkline-poland/","https://www.youtube.com/user/gskasiachannel/","https://www.youtube.com/channel/UChWuz9ZDceHYHXmJVJ4hF8Q","https://www.youtube.com/channel/UCN1XeWQWLVhFLHQwZl93jFQ","https://www.youtube.com/channel/UCwQyIfV4pLlsZGuN7fiZm2w","https://twitter.com/gsk_ar","https://twitter.com/GSK_Asia","https://twitter.com/gsk_conferences","https://twitter.com/gsk_au","https://twitter.com/GSK_DE","https://twitter.com/GSKCH_INDIA","https://twitter.com/GSK_IE","https://twitter.com/gsk_it","https://twitter.com/GSKScience","https://twitter.com/stiefel","https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/","https://www.gsk.com/en-gb/behind-the-science/innovation/the-digitalisation-lab-bringing-the-digital-age-to-manufacturing/","https://www.gsk.com/en-gb/careers/meet-our-people/lindsay-rd-uk/","http://uk.gsk.com/en-gb/careers/apprenticeships/","https://www.gsk.com/media/4931/gsk-quick-facts.pdf","https://ie.gsk.com/ie/careers/apprenticeships/","http://au.gsk.com/en-au/careers/apprenticeships/","http://sg.gsk.com/en-sg/careers/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/","https://gsk.i-sight.com/landing-page/","https://www.gskforyou.com/","https://jobs.gsk.com/en-us/jobs?keywords=RichmondConsumerHealthcareR%26D&page=1","https://jobs.gsk.com/en-us/jobs?page=1&location=Lincoln,%20NE,%20United%20States&woe=7&stretch=10&stretchUnit=KILOMETERS&keywords=manufacturing&sortBy=relevance","https://jobs.gsk.com/en-us/jobs?page=1&location=Carlisle,%20PA,%20United%20States&woe=7&stretch=10&stretchUnit=KILOMETERS&keywords=manufacturing&sortBy=relevance","https://jobs.gsk.com/en-us/jobs?page=1&location=East%20Durham,%20NY,%20United%20States&woe=7&stretch=10&stretchUnit=KILOMETERS&keywords=manufacturing&sortBy=relevance","https://us.gsk.com/en-us/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status/","https://privacy.gsk.com/en-us/privacy-notice/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2020/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2021/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/en-gb/company/codes-standards-and-reports/","https://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/media/our-response-to-covid-19/","https://www.gsk.com/en-gb/behind-the-science-magazine/","https://www.gsk.com/en-gb/media/","https://www.gsk.com/en-gb/behind-the-science/","https://gskpro.com/","https://viivhealthcare.com/","https://www.gsk-studyregister.com/en/","https://gsk.supplierone.co/","https://www.gsk.com/en-gb/investors/financial-reports/","https://www.gsk.com/en-gb/investors/dividend-and-share-price/","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/speakup","https://www.gsk.com/en-gb/company/outstanding-people/","https://www.gsk.com/en-gb/company/policy-positions","https://www.gsk.com/en-gb/research-and-development/our-approach-to-rd/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/en-gb/company/policy-positions/#","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://www.togetherwithgskoncology.com/","https://www.gsk.com/en-gb/behind-the-science/looking-deeper-into-lupus/","https://gateway.on24.com/wcc/eh/3471076/Patient+Engagement+Hub","https://www.gsk.com/en-gb/behind-the-science/following-the-science-of-oxygen-to-discover-solutions-for-anaemia/","https://www.multivu.com/players/English/8857131-gsk-ask2bsure-meningitis-b-vaccination/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk.com/en-gb/innovation/","https://www.gsk.com/en-gb/behind-the-science/mrna-messenger-ribonucleic-acid-disrupting-the-field-of-vaccinology/","https://www.gsk.com/en-gb/behind-the-science/inside-the-vaccine-factory-of-the-future/","https://www.gsk-studyregister.com/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/diversity-equity-and-inclusion/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://www.gsk.com/media/8518/policies-and-standards.pdf","https://www.gsk.com/en-gb/company/governance/compliance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/working-with-third-parties/","https://www.gsk.com/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","https://www.gsk.com/en-gb/responsibility/ethical-standards/human-rights/","https://www.gsk.com/en-gb/responsibility/ethical-standards/use-of-animals/","https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","https://www.gsk.com/en-gb/media/press-releases/","https://annualreport.gsk.com/","https://www.gsk.com/en-gb/media/media-contacts/","https://www.gsk.com/en-gb/media/media-library/","https://www.gsk.com/en-gb/media/social-media/","https://www.gsk.com/en-gb/media/our-response-to-the-situation-in-ukraine/","https://jobs.gsk.com/en-us/jobs?keywords=%23ApprenticeUS&location=&lang=en-us","https://www.gsk.com/en-gb/behind-the-science/advancing-the-next-generation-of-immuno-oncology/","https://www.gsk.com/en-gb/behind-the-science/synthetic-lethality-outmanoeuvring-the-cancer-genome/","https://www.gsk.com/en-gb/media/press-releases/gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies/","https://jobs.gsk.com/en-us/jobs?keywords=oncology&page=1","https://jobs.gsk.com/en-us/jobs?keywords=oncology&page=1","https://www.gsk.com/en-gb/research-and-development/our-pipeline/","https://jobs.gsk.com/en-us/jobs?keywords=%23WYARD2022&location=&lang=en-us","https://jobs.gsk.com/en-us/jobs?keywords=%23WYAcommerical2022&lang=en-us&sortBy=relevance&page=1","https://jobs.gsk.com/en-us/jobs?keywords=%23WYAGSC2022&lang=en-us&sortBy=relevance&page=1","https://jobs.gsk.com/en-us/jobs?lang=en-us&sortBy=relevance&page=1&location=United%20States&woe=12&stretchUnit=MILES&stretch=10","https://www.gsk.com/media/8520/the-code-presentation-version.pdf","https://www.gsk.com/en-gb/careers/featured-careers/","https://www.gsk.com/en-gb/careers/how-we-hire/","https://www.gsk.com/en-gb/careers/our-global-and-regional-hubs/","https://www.gsk.com/en-gb/careers/how-we-hire/frequently-asked-questions/","https://supplier.gsk.com/irj/portal/public","http://www.gsk.com/en-gb/contact-us/worldwide/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/enquiries-privacy-notice/","https://gskpro.com/en-us/","https://gskpro.com/","https://gskpro.com","https://www.gsk.com/en-gb/responsibility/esg-resources/","http://www.gskfunding.com/","https://www.gsk.com/en-gb/behind-the-science-magazine/prevention-best-medicine-disease-patients/","https://www.gsk.com/en-gb/behind-the-science-magazine/men-women-gender-diversity-clinical-trials/","https://www.gsk.com/en-gb/behind-the-science-magazine/maps-technology-new-age-vaccine-development-infectious-diseases/","https://www.gsk.com/en-gb/investors/speeches-and-presentations/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://contactus.gsk.com/","https://gsk.connectr.co.uk/getahead/","https://www.linkedin.com/company/gsk/","https://x.com/GSKUS?mx=2","https://www.facebook.com/GSK/","https://jobs.gsk.com/?lang=en-us&previousLocale=en-US","https://jobs.gsk.com/en-us/jobs?keywords=%23USCommercialDevelopmentProgram&page=1&sortBy=relevance?keywords=%23USCommercialDevelopmentProgram&page=1&sortBy=relevance&location=United%20States","https://jobs.gsk.com/?lang=en-us&previousLocale=en-US","https://jobs.gsk.com/en-us/jobs?keywords=&location=&lang=en-us?keywords=%23ApprenticeUS2026&page=1&sortBy=relevance&location=United%20States&stretch=10&stretchUnit=MILES?keywords=%23ApprenticeUS2025%20&page=1&sortBy=relevance&location=United%20States","https://www.vaccinetrack.com/Trend?tab=gap&vaccine=9&timePeriod=2021","https://jobs.gsk.com/en-us/jobs?keywords=&location=&lang=en-us","http://tinyurl.com/mrt9buj2","https://jobs.gsk.com/en-gb/jobs?location=Massachusetts,%20United%20States&locations=Boston,Massachusetts,United%20States%7CCambridge,Massachusetts,United%20States%7CWaltham,Massachusetts,United%20States&page=1&stretch=10&stretchUnit=MILES&woe=8","https://jobs.gsk.com/en-us/jobs?keywords=%23USCommercialDevelopmentProgram&sortBy=relevance&page=1&location=United%20States&woe=12®ionCode=US&stretchUnit=MILES&stretch=50","https://jobs.gsk.com/en-us/jobs?keywords=%23USCommercialDevelopmentProgram&page=1&sortBy=relevance&location=United%20States?keywords=%23ApprenticeUS&location=&lang=en-us","https://x.com/GSKUS","https://ourwayforward.com/content/dam/brs-pharma-us/ourwayforward-dtc/en_US/pdfs/oc-patient-discussion-guide.pdf","https://gsk.public.reportum.com/","https://password.gsk.com/password/","https://uksah.gsk.com/swh_uk_win_ns/communications/employee/employees.htm","https://www.vaccinetrack.com/Trend?tab=gap&timePeriod=2022&timePeriod2=2021","https://gskvaccination.com/","https://jobs.gsk.com/en-gb/jobs?lang=en-gb&page=1&location=Massachusetts,%20United%20States&woe=8&stretchUnit=MILES&stretch=10&locations=Boston,Massachusetts,United%20States%7CCambridge,Massachusetts,United%20States%7CWaltham,Massachusetts,United%20States&utm_source=direct&utm_campaign=25453&utm_medium=symphonytalent-misctags&utm_term=43516_Boston%20In-House","https://dontbeembarrassed.com/","https://www.vaccinetrack.com","https://scienceinthesummer.fi.edu/","https://jobs.gsk.com/en-gb/jobs?location=United%20States&locations=Boston,Massachusetts,United%20States%7CCambridge,Massachusetts,United%20States%7CWaltham,Massachusetts,United%20States&page=1&stretch=10&stretchUnit=MILES&woe=8","https://us.gsk.com/en-us/media/press-releases/julie-bowen-and-ty-burrell-team-up-with-gsk-to-raise-awareness-about-meningitis-risks-for-teens-and-young-adults/","https://us.gsk.com/en-us/contact-us/","https://jobs.gsk.com/gb/en/search-results?m=3&keywords=%23ApprenticeUS2026","https://jobs.gsk.com/gb/en/search-results?m=3&keywords=Oncology","https://jobs.gsk.com/gb/en/ih-boston-all"]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://us.gsk.com/media/kzafk31i/gsk-logo.png?width=104&format=webp&quality=100&v=1dbe12293a58ec0&hmac=a25f7108d09d8a8b732fbd04251a2fa28e97f61e629cff7623307613eeca2cd3","alt":"Gsk Logo (1)","darkModeSrc":"https://us.gsk.com/media/kzafk31i/gsk-logo.png?width=104&format=webp&quality=90&v=1dbe12293a58ec0&hmac=f91ed576717ab1f54deea0aaa180f5beb38518837d85f98823323fde477e1f38"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK US"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://us.gsk.com/en-us/media/press-releases/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhea/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":null}